Can Fite Biofarma (Can Fite Biofarma) Price-to-Tangible-Book : 1.52 (As of May. 04, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Can Fite Biofarma Price-to-Tangible-Book?

As of today (2024-05-04), Can Fite Biofarma's share price is $2.09. Can Fite Biofarma's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $1.38. Hence, Can Fite Biofarma's Price to Tangible Book Ratio of today is 1.52.

The historical rank and industry rank for Can Fite Biofarma's Price-to-Tangible-Book or its related term are showing as below:

CANF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2 Med: 4.44 Max: 8.79
Current: 2.68

During the past 13 years, Can Fite Biofarma's highest Price to Tangible Book Ratio was 8.79. The lowest was 2.00. And the median was 4.44.

CANF's Price-to-Tangible-Book is ranked better than
52.95% of 1222 companies
in the Biotechnology industry
Industry Median: 2.75 vs CANF: 2.68

A closely related ratio is called PB Ratio. As of today, Can Fite Biofarma's share price is $2.09. Can Fite Biofarma's Book Value per Sharefor the quarter that ended in Dec. 2023 was $1.38. Hence, Can Fite Biofarma's P/B Ratio of today is 1.52.

Can Fite Biofarma Price-to-Tangible-Book Historical Data

The historical data trend for Can Fite Biofarma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Price-to-Tangible-Book Chart

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

5.43

4.53

2.44

3.73

1.60

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															3.73	1.10	1.82	2.07	1.60

Competitive Comparison of Can Fite Biofarma's Price-to-Tangible-Book

For the Biotechnology subindustry, Can Fite Biofarma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biofarma's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Price-to-Tangible-Book falls into.

Can Fite Biofarma Price-to-Tangible-Book Calculation

Can Fite Biofarma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	2.09	/	1.377
	=	1.52

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Can Fite Biofarma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).